We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics

FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics  content piece image
Credit: FairJourney Biologics
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS) today announced they have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). The partnership will harness both FJB and IONTAS’ proprietary antibody libraries and technology platforms to investigate novel therapeutic targets for autoimmune and inflammatory diseases.

Pandion focuses on the development of innovative modular therapeutics using its TALON™ (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform. The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system. In conjunction with a tissue-specific targeting moiety, the effectors create novel bifunctional molecules for the treatment of autoimmune and inflammatory diseases.

Under the terms of the agreement, Pandion will access the novel libraries and platform technologies provided by FJB and IONTAS. A dedicated FJB/IONTAS FTE will be assigned to the project with the aim of discovering diverse panels of novel target binders for use within the TALON platform. The Agreement extends an existing relationship between the companies and gives Pandion the option to use standard phage display or mammalian display as the engines for the discovery of next generation antibodies. 

Dr António Parada, CEO at FairJourney Biologics and IONTAS, commented: “Our teams have gained considerable experience in antibody discovery for use in generating mono-specific and bi-specific therapeutics. We now have a pipeline of undisclosed therapeutic partnerships nearing clinical research. We look forward to continuing our relationship with Pandion and applying our experience and expertise to generate a diverse set of antibodies for further study.”

Dr Hussam Shaheen, Director of Antibody Discovery and Engineering at Pandion Therapeutics, said: “Our TALON platform leverages natural immune regulatory mechanisms, to re-balance immune responses and ultimately advance discovery into novel treatments for autoimmune and inflammatory diseases. The experience in antibody discovery shared by FJB and IONTAS, together with their unique library of target binders, makes them ideal partners as we focus on successfully progressing these transformational therapies to patients in need.”